Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels.
about
Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central ItalyHIV-1 drug resistance and resistance testing.A Robust PCR Protocol for HIV Drug Resistance Testing on Low-Level Viremia Samples.Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia.Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithmHIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing.HIV-1 persistent viremia is frequently followed by episodes of low-level viremia.Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression.Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study.Determinants of virological failure and antiretroviral drug resistance in Mozambique.Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens.Projecting the epidemiological effect, cost-effectiveness and transmission of HIV drug resistance in Vietnam associated with viral load monitoring strategies.Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains.Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study.Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice.HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.Interplay Between Transmitted and Acquired HIV Type 1 Drug Resistance: Reasons for a Disconnect.Feasibility and reproducibility of HIV-1 genotype resistance test in very-low-level viremia.Editorial Commentary: Extending HIV drug resistance testing to low levels of plasma viremia.Human Immunodeficiency Virus Resistance Testing Technologies and Their Applicability in Resource-Limited Settings of Africa.Alternative Sample Types for HIV-1 Antiretroviral Drug Resistance Testing.Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children.Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence
P2860
Q28547222-CBDAA926-D3E4-4778-AEA2-2FF1C73C0349Q30245693-5C8AFCA2-6829-4236-8F17-F05A28D3DE48Q33572108-5B325FAA-3CF1-437E-A3A3-40065EEF3940Q33963458-F96C5BF9-C457-426D-952F-21C3A42E5298Q35577906-992C1DFB-FE6C-4E36-B5C2-C3D41288354CQ35698144-96D91A1F-B3C8-4002-BA76-A81EED12B10FQ35968753-67370165-696D-4233-A742-04402216C18CQ36050916-014899E8-1D1F-49B3-9360-00CFA82A376AQ38375479-55D47595-8F40-447A-AF17-32BFB4790628Q38951030-B3B8CAEA-D6B3-406D-B2F4-6A7583F7C803Q39311484-0F271DB1-3D65-4F8A-BF05-3397D231FC79Q39375437-5C6ED37E-3E1E-4C06-BF82-A3BC85BEA0DEQ39414398-78AB30D5-9A8E-47E1-BB7F-33D37AD76AE3Q39648233-4B6CA33A-B758-415E-AD6B-806BEC66DFD3Q40002754-D8FE5320-0522-45AA-8782-F941E61F9390Q40137561-5D3908EC-31DA-47FA-A8DD-953287DC11ACQ40278469-52364AF7-2498-402E-9875-3AA7EE43910EQ40401616-8FD7C2B1-04FA-423C-8ACB-EC9C82B53D73Q40463006-4DE2731B-5EB3-4F3F-A58D-7821BD2BE7CDQ41276669-7A359B2C-B943-4CCD-A5F3-1CC2291E9E13Q41465991-DDCB0492-2D20-48B2-8163-208A6C777D69Q42533699-9823E816-B0D6-419C-8D96-3339F8795B12Q43045837-3B73F993-008E-4756-AE3B-D81BE2FEBD07Q44864490-ED9A9C0D-3A59-42F1-B248-2E2133F36225Q47113253-A3B9F3D7-325C-4277-8872-7FB2F3064EE7Q47613741-580C7C79-8900-49E1-8B1C-80F51A8003B8Q55224546-F61A4D11-CADB-4971-82DD-B5968DCB75F0Q57794708-B26A113D-85B0-453A-8BD4-1035575E4F4E
P2860
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Reliability and clinical relev ...... ients with low viremia levels.
@en
Reliability and clinical relev ...... ients with low viremia levels.
@nl
type
label
Reliability and clinical relev ...... ients with low viremia levels.
@en
Reliability and clinical relev ...... ients with low viremia levels.
@nl
prefLabel
Reliability and clinical relev ...... ients with low viremia levels.
@en
Reliability and clinical relev ...... ients with low viremia levels.
@nl
P2093
P2860
P50
P356
P1476
Reliability and clinical relev ...... ients with low viremia levels.
@en
P2093
Chiara Tommasi
Daniele Armenia
Domenico Di Carlo
Domenico Di Pinto
Evangelo Boumis
Gianpiero D'Offizi
Roberta D'Arrigo
P2860
P304
P356
10.1093/CID/CIU020
P407
P50
P577
2014-01-14T00:00:00Z